Claims for Patent: 8,614,228
✉ Email this page to a colleague
Summary for Patent: 8,614,228
Title: | Quinone prodrug compositions and methods of use |
Abstract: | The present invention relates to quinone prodrug compositions and therapeutic methods using such prodrug compositions. Preferably, the quinone compounds of the invention are napthoquinone compounds such as .beta.-lapachone or .beta.-lapachone analogs. The quinone prodrug compositions of the invention exhibit improved solubility, stability, bioavailability, and pharmacokinetic properties, as well as improved plasma half-life in vivo. |
Inventor(s): | Ashwell; Mark A. (Carlisle, MA), Tandon; Manish (Framingham, MA), Lapierre; Jean-Marc (Pelham, NH), Liu; Yanbin (Acton, MA) |
Assignee: | ArQule, Inc. (Woburn, MA) |
Application Number: | 11/201,170 |
Patent Claims: | 1. A quinone prodrug composition comprising a quinone compound of formula I ##STR00062## wherein R.sub.1 is H or C.sub.1-C.sub.4 alkyl, optionally substituted with a sulfyl
(--SH or thio alkyl) group; R.sub.4 is C.sub.1-C.sub.4 alkyl, aryl or heteroaryl, wherein said aryl or heteroaryl is selected from the group consisting of phenyl, pyridyl, imidazole and thiazole, and is optionally substituted with one or more
independently selected C.sub.1-C.sub.3 alkyl groups; the pro-moiety is selected from --(C.sub.1-C.sub.11)alkyl, --(C.sub.0-C.sub.6)alkyl-aryl, --(C.sub.0-C.sub.6)alkyl-heteroaryl, --(C.sub.0-C.sub.6)alkyl-aryl-heteroaryl, --(C.sub.0-C.sub.6)alkyl-COOH,
--(C.sub.1-C.sub.6)alkyl-OH, 1-pyridyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, aryl-heteroaryl, ##STR00063## and n is 0, 1, 2 or 3, with the proviso that when n is 0, R.sub.1 is not present.
2. The quinone prodrug composition of claim 1, wherein the quinone compound is .beta.-lapachone. 3. A quinone prodrug composition, wherein the composition is a compound selected from the group consisting of ##STR00064## ##STR00065## ##STR00066## 4. A pharmaceutical composition comprising a therapeutically effective amount of at least one quinone prodrug composition and a pharmaceutically acceptable excipient, wherein said quinone prodrug composition comprises a quinone compound of formula I ##STR00067## wherein R.sub.1 is H or C.sub.1-C.sub.4 alkyl, optionally substituted with a sulfyl (--SH or thio alkyl) group; R.sub.4 is C.sub.1-C.sub.4 alkyl, aryl or heteroaryl, wherein said aryl or heteroaryl is selected from the group consisting of phenyl, pyridyl, imidazole and thiazole, and is optionally substituted with one or more independently selected C.sub.1-C.sub.3 alkyl groups; the pro-moiety is selected from --(C.sub.1-C.sub.11)alkyl, --(C.sub.0-C.sub.6)alkyl-aryl, --(C.sub.0-C.sub.6)alkyl-heteroaryl, --(C.sub.0-C.sub.6)alkyl-aryl-heteroaryl, --(C.sub.0-C.sub.6)alkyl-COOH, --(C.sub.1-C.sub.6)alkyl-OH, 1-pyridyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, aryl-heteroaryl, ##STR00068## and n is 0, 1, 2 or 3, with the proviso that when n is 0, R.sub.1 is not present. 5. The pharmaceutical composition of claim 4, wherein the pharmaceutical composition is an aqueous solution. 6. The pharmaceutical composition of claim 4, wherein the pharmaceutical composition is a lyophilized solid. 7. The pharmaceutical composition of claim 4, wherein the pharmaceutical composition comprises 0.1 mg/ml to 10 mg/ml of the quinone prodrug composition. 8. The pharmaceutical composition of claim 4, further comprising a second anticancer agent. 9. The pharmaceutical composition of claim 8, wherein the second anticancer agent is selected from the group consisting of taxane derivatives, gemcitabine, cisplatin, imatnibmeasylate, and trastuzumab. 10. The pharmaceutical composition of claim 9, wherein the taxane derivative is paclitaxel or docetaxol. 11. A kit for the treatment of a mammalian cancer comprising at least one vial containing a quinone prodrug composition of claim 1. 12. A kit of claim 11, wherein the kit further comprises, within in the same vial or a separate vial, a second anticancer agent. 13. The kit of claim 12, wherein the second anticancer agent is selected from the group consisting of taxane derivatives, gemcitabine, cisplatin, imatnibmeasylate, and trastuzumab. 14. The kit of claim 13, wherein the taxane derivative is paclitaxel or docetaxol. 15. The quinone prodrug composition of claim 1, wherein R.sub.4 is methyl. 16. The quinone prodrug composition of claim 1, wherein said aryl is phenyl. 17. The quinone prodrug composition of claim 1, wherein said aryl is substituted with C.sub.1-C.sub.6 alkyl. 18. The quinone prodrug composition of claim 1, wherein said heteroaryl is selected from the group consisting of pyridyl, imidazole and thiazole. 19. The quinone prodrug composition of claim 1, wherein said heteroaryl is substituted with C.sub.1-C.sub.6 alkyl. 20. The quinone prodrug composition of claim 1, wherein said pro-moiety is selected from --COOH, --CH.sub.2--COOH and --(CH.sub.2).sub.2--COOH. |
Details for Patent 8,614,228
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2024-08-11 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2024-08-11 |
Genentech, Inc. | HERCEPTIN HYLECTA | trastuzumab and hyaluronidase-oysk | Injection | 761106 | 02/28/2019 | ⤷ Try a Trial | 2024-08-11 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.